Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
Resource Type
Article
Authors
Toledo-Romaní, María Eugenia ; García-Carmenate, Mayra ; Valenzuela-Silva, Carmen ; Baldoquín-Rodríguez, Waldemar ; Martínez-Pérez, Marisel ; Rodríguez-González, Meiby ; Paredes-Moreno, Beatriz ; Mendoza-Hernández, Ivis ; González-Mujica Romero, Raúl ; Samón-Tabio, Oscar ; Velazco-Villares, Pablo ; Bacallao-Castillo, Juan Pablo ; Licea-Martín, Ernesto ; Rodríguez-Ortega, Misladys ; Herrera-Marrero, Nuris ; Caballero-González, Esperanza ; Egües-Torres, Liudmila ; Duartes-González, Reinaldo ; García-Blanco, Serguey ; Pérez-Cabrera, Suzette ; Huete-Ferreira, Santos ; Idalmis-Cisnero, Kirenia ; Fonte-Galindo, Omayda ; Meliá-Pérez, Dania ; Rojas-Remedios, Ivonne ; Doroud, Delaram ; Gouya, Mohammad Mehdi ; Biglari, Alireza ; Fernández-Castillo, Sonsire ; Climent-Ruiz, Yanet ; Valdes-Balbín, Yury ; García-Rivera, Dagmar ; Van der Stuyft, Patrick ; Verez-Bencomo, Vicente
Source
In The Lancet Regional Health - Americas February 2023 18
Subject
Language
ISSN
2667-193X